Literature DB >> 20959785

Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction.

Jonathan P Piccini1, Phillip J Schulte, Karen S Pieper, Rajendra H Mehta, Harvey D White, Frans Van de Werf, Diego Ardissino, Robert M Califf, Christopher B Granger, E Magnus Ohman, John H Alexander.   

Abstract

OBJECTIVE: Few data exist to guide antiarrhythmic drug therapy for sustained ventricular tachycardia/ventricular fibrillation after acute myocardial infarction. The objective of this analysis was to describe the survival of patients with sustained ventricular tachycardia/ventricular fibrillation after myocardial infarction according to antiarrhythmic drug treatment. DESIGN AND
SETTING: We conducted a retrospective analysis of ST-segment elevation myocardial infarction patients with sustained ventricular tachycardia/ventricular fibrillation in Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO) IIB and GUSTO III and compared all-cause death in patients receiving amiodarone, lidocaine, or no antiarrhythmic. We used Cox proportional-hazards modeling and inverse weighted estimators to adjust for baseline characteristics, β-blocker use, and propensity to receive antiarrhythmics. Due to nonproportional hazards for death in early follow-up (0-3 hrs after sustained ventricular tachycardia/ventricular fibrillation) compared with later follow-up (>3 hrs), we analyzed all-cause mortality using time-specific hazards. PATIENTS AND
INTERVENTIONS: Among 19,190 acute myocardial infarction patients, 1,126 (5.9%) developed sustained ventricular tachycardia/ventricular fibrillation and met the inclusion criteria. Patients received lidocaine (n = 664, 59.0%), amiodarone (n = 50, 4.4%), both (n = 110, 9.8%), or no antiarrhythmic (n = 302, 26.8%).
RESULTS: In the first 3 hrs after ventricular tachycardia/ventricular fibrillation, amiodarone (adjusted hazard ratio 0.39, 95% confidence interval 0.21-0.71) and lidocaine (adjusted hazard ratio 0.72, 95% confidence interval 0.53-0.96) were associated with a lower hazard of death-likely evidence of survivor bias. Among patients who survived 3 hrs, amiodarone was associated with increased mortality at 30 days (adjusted hazard ratio 1.71, 95% confidence interval 1.02-2.86) and 6 months (adjusted hazard ratio 1.96, 95% confidence interval 1.21-3.16), but lidocaine was not at 30 days (adjusted hazard ratio 1.19, 95% confidence interval 0.77-1.82) or 6 months (adjusted hazard ratio 1.10, 95% confidence interval 0.73-1.66).
CONCLUSION: Among patients with acute myocardial infarction complicated by sustained ventricular tachycardia/ventricular fibrillation who survive 3 hrs, amiodarone, but not lidocaine, is associated with an increased risk of death, reinforcing the need for randomized trials in this population.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20959785      PMCID: PMC3010352          DOI: 10.1097/CCM.0b013e3181fd6ad7

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  20 in total

1.  Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study.

Authors:  Jared K Lunceford; Marie Davidian
Journal:  Stat Med       Date:  2004-10-15       Impact factor: 2.373

2.  Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.

Authors:  A L Waldo; A J Camm; H deRuyter; P L Friedman; D J MacNeil; J F Pauls; B Pitt; C M Pratt; P J Schwartz; E P Veltri
Journal:  Lancet       Date:  1996-07-06       Impact factor: 79.321

3.  A comparison of reteplase with alteplase for acute myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1997-10-16       Impact factor: 91.245

4.  Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation.

Authors:  Paul Dorian; Dan Cass; Brian Schwartz; Richard Cooper; Robert Gelaznikas; Aiala Barr
Journal:  N Engl J Med       Date:  2002-03-21       Impact factor: 91.245

5.  A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes.

Authors: 
Journal:  N Engl J Med       Date:  1996-09-12       Impact factor: 91.245

6.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1989-08-10       Impact factor: 91.245

7.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction).

Authors:  Elliott M Antman; Daniel T Anbe; Paul Wayne Armstrong; Eric R Bates; Lee A Green; Mary Hand; Judith S Hochman; Harlan M Krumholz; Frederick G Kushner; Gervasio A Lamas; Charles J Mullany; Joseph P Ornato; David L Pearle; Michael A Sloan; Sidney C Smith; Joseph S Alpert; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Raymond J Gibbons; Gabriel Gregoratos; Jonathan L Halperin; Loren F Hiratzka; Sharon Ann Hunt; Alice K Jacobs
Journal:  Circulation       Date:  2004-08-03       Impact factor: 29.690

8.  Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification.

Authors:  A John Camm; Craig M Pratt; Peter J Schwartz; Hussein R Al-Khalidi; Maria J Spyt; Michael J Holroyde; Roger Karam; Edmund H Sonnenblick; Jose M G Brum
Journal:  Circulation       Date:  2004-02-16       Impact factor: 29.690

9.  Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction.

Authors:  L K Hine; N Laird; P Hewitt; T C Chalmers
Journal:  Arch Intern Med       Date:  1989-12

10.  Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators.

Authors:  K L Lee; L H Woodlief; E J Topol; W D Weaver; A Betriu; J Col; M Simoons; P Aylward; F Van de Werf; R M Califf
Journal:  Circulation       Date:  1995-03-15       Impact factor: 29.690

View more
  9 in total

1.  Amiodarone and lidocaine for shock refractory ventricular fibrillation or ventricular tachycardia in out-of-hospital cardiac arrest: are they really effective?

Authors:  Kazuhiro Sugiyama; Masahiro Kashiura; Yuichi Hamabe
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

2.  Ventricular Arrhythmia after Acute Myocardial Infarction: 'The Perfect Storm'.

Authors:  Justine Bhar-Amato; William Davies; Sharad Agarwal
Journal:  Arrhythm Electrophysiol Rev       Date:  2017-08

3.  Practical Aspects of the Use of Telematic Systems in the Diagnosis of Acute Coronary Syndrome in Poland.

Authors:  Lukasz Gawinski; Monika Burzynska; Karolina Kamecka; Remigiusz Kozlowski
Journal:  Medicina (Kaunas)       Date:  2022-04-17       Impact factor: 2.948

4.  Safety measures for COVID-19 do not compromise the outcomes of patients undergoing primary percutaneous coronary intervention: a single center retrospective study.

Authors:  Xiaonan Guan; Jianjun Zhang; Yanbing Li; Ning Ma
Journal:  Sci Rep       Date:  2021-05-11       Impact factor: 4.379

Review 5.  Ventricular Arrhythmias in First Acute Myocardial Infarction: Epidemiology, Mechanisms, and Interventions in Large Animal Models.

Authors:  Stefan Michael Sattler; Lasse Skibsbye; Dominik Linz; Anniek Frederike Lubberding; Jacob Tfelt-Hansen; Thomas Jespersen
Journal:  Front Cardiovasc Med       Date:  2019-11-05

6.  Colchicine to Prevent Sympathetic Denervation after an Acute Myocardial Infarction: The COLD-MI Trial Protocol.

Authors:  Fabien Huet; Quentin Delbaere; Sylvain Aguilhon; Valentin Dupasquier; Delphine Delseny; Richard Gervasoni; Jean-Christophe Macia; Florence Leclercq; Nidal Jammoul; Sandra Kahlouche; Sonia Soltani; Fanny Cardon; Anne-Marie Dupuy; Jean-Paul Cristol; Denis Mariano-Goulart; Myriam Akodad; Nicolas Nagot; François Roubille
Journal:  Medicina (Kaunas)       Date:  2021-09-30       Impact factor: 2.430

Review 7.  Prophylactic lidocaine for myocardial infarction.

Authors:  Arturo J Martí-Carvajal; Daniel Simancas-Racines; Vidhu Anand; Shrikant Bangdiwala
Journal:  Cochrane Database Syst Rev       Date:  2015-08-21

8.  Meta-analysis of the efficacies of amiodarone and nifekalant in shock-resistant ventricular fibrillation and pulseless ventricular tachycardia.

Authors:  Shiho Sato; Yoshito Zamami; Toru Imai; Satoshi Tanaka; Toshihiro Koyama; Takahiro Niimura; Masayuki Chuma; Tadashi Koga; Kenshi Takechi; Yasuko Kurata; Yutaka Kondo; Yuki Izawa-Ishizawa; Toshiaki Sendo; Hironori Nakura; Keisuke Ishizawa
Journal:  Sci Rep       Date:  2017-10-04       Impact factor: 4.379

9.  Cardioprotective effect of sonic hedgehog ligand in pig models of ischemia reperfusion.

Authors:  Bijan Ghaleh; Jérôme Thireau; Olivier Cazorla; Raffaella Soleti; Valérie Scheuermann; Alain Bizé; Lucien Sambin; François Roubille; Ramaroson Andriantsitohaina; Maria Carmen Martinez; Alain Lacampagne
Journal:  Theranostics       Date:  2020-03-04       Impact factor: 11.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.